Generic Name: fremanezumab
Brand Name: Ajovy
Manufacturer: Teva Canada Innovation
Therapeutic Area: migraine
Indications: Indicated for the prevention of migraine in adults who have at least 4 migraine days per month.
Manufacturer Requested Reimbursement Criteria1: For the prevention of migraine in adults who have at least 4 migraine days per month.
Submission Type: Initial
Project Status: Active
Companion Diagnostics: No
Fee Schedule: Schedule A
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
|Call for patient input open||March 30, 2020|
|Call for patient input closed||May 20, 2020|
- Patient input submission received from Migraine Canada and Migraine Quebec
|Submission received||June 03, 2020|
|Submission accepted||September 22, 2020|
- Submission was not accepted for review on 17 June 2020
|Review initiated||September 23, 2020|
|Draft CADTH review report(s) provided to sponsor for comment||December 09, 2020|
|Deadline for sponsors comments||December 18, 2020|
|CADTH responses on draft review report(s) provided to sponsor||February 04, 2021|
|Expert committee meeting (initial)||February 17, 2021|
|Draft recommendation issued to sponsor||March 01, 2021|
March 03, 2021